Department: Wolfson Institute of Population HealthSalary: £38,165 - £44,722 per annum (Grade 4)Reference: 2603Location: WhitechapelDate posted: 27 June 2024Closing date: 11 July 2024
Further details and apply
About the Role
This post represents an exciting opportunity for a self-motivated individual to develop their monitoring skills while working on a multi-site IMP trial. Whilst the post is based at Whitechapel with the PCTU, the holder will be required to travel to up to 25 study sites throughout the UK. Overnight stay when conducting 2-day site visits is likely to be required.
About You
The successful candidate will have previous research experience in multi-site Clinical Trials of an Investigational Medicinal Product (CTIMPs) is essential. Previous Monitoring experience would be beneficial.
About the School/Department/Institute/Project
#ChariotMS is a multi-centre, randomised, double-blind, placebo-controlled, phase IIb trial. The aim is to test oral cladribine (Mavenclad®) compared to placebo for safety, efficacy, and cost-effectiveness and to advance mechanistic understanding in people with advanced Multiple Sclerosis (MS), i.e. disability severe enough to limit their ability to walk beyond a short distance with support, or not being able to walk at all, but with some retained upper limb function.
Job purpose
The post-holder will join the Quality Assurance team working within the PCTU on a wide variety of trials (CTIMPs and non-CTIMPs), and observational studies at different stages of their development and completion. The team works to ensure that the all research supported by the PCTU complies with Regulatory requirements and best practice guidelines.
#ChariotMS is a multi-centre, randomised, double-blind, placebo-controlled, phase IIb trial. The aim of the trial is to test oral cladribine (Mavenclad®) compared to placebo for safety, efficacy, and cost-effectiveness and to advance mechanistic understanding in people with advanced Multiple Sclerosis (MS), i.e. disability severe enough to limit their ability to walk beyond a short distance with support, or not being able to walk at all, but with some retained upper limb function. #ChariotMS is the first ever disease modifying treatment (DMT) trial focussing on people with MS at this stage of disability. It is expected that the trial will provide evidence to support widespread NHS, and international, adoption of cladribine as a treatment in people with advanced MS. About Queen Mary
At Queen Mary University of London, we believe that a diversity of ideas helps us achieve the previously unthinkable. Throughout our history, we’ve fostered social justice and improved lives through academic excellence. And we continue to live and breathe this spirit today, not because it’s simply ‘the right thing to do’ but for what it helps us achieve and the intellectual brilliance it delivers. We continue to embrace diversity of thought and opinion in everything we do, in the belief that when views collide, disciplines interact, and perspectives intersect, truly original thought takes form. Benefits
We offer competitive salaries, access to a generous pension scheme, 30 days’ leave per annum (pro-rata for part-time/fixed-term), a season ticket loan scheme and access to a comprehensive range of personal and professional development opportunities. In addition, we offer a range of work life balance and family friendly, inclusive employment policies, campus facilities and flexible working arrangements.
Queen Mary’s commitment to our diverse and inclusive community is embedded in our appointments processes. Reasonable adjustments will be made at each stage of the recruitment process for any candidate with a disability. We are open to considering applications from candidates wishing to work flexibly.